 [43][44][45][46] 1992) 
etoacetase. and in three tvrosinemia families in which one or both are compound heterozygotes for the tyrosinemia and pseudodeficiency genes. Liver extracts from two chronic patients were also investigated. None of the patients with the acute type of tyrosinemia had detectable immunoreactive protein in fibroblast extracts. Only two of seven patients with typical chronic tyrosinemia had definite immunoreactivity in fibroblasts. In liver tissue, one of the patients had cross-reactive material and the other had no immunoreactivity. Four of 13 patients with intermediate clinical findings showed immunoreactivity in fibroblasts. There was no relationship between severity of symptoms and amount of cross-reactive material in this group. The pseudodeficiency gene product gave almost no detectable immunoreactivity in fibroblasts. The results indicate that chronic tyrosinemia may be due to at least two protein variants, and immunoblotting does not classify tyrosinemia patients according to clinical findings. (Pediatr Res 31: [43] [44] [45] [46] 1992) Abbreviations FAH, fumarylacetoacetase the acute form of tyrosinemia lack immunoreactive FAH protein, whereas patients with the chronic form have varying amounts of cross-reactive material (1, (3) (4) (5) (6) . In these reports, very few patients with chronic tyrosinemia were investigated. To decide if there is a consistent difference between acute and chronic tyrosinemia patients with regard to amount of immunoreactive FAH protein, we have performed Western blotting in fibroblast extracts from 28 patients with varying clinical pictures. In two chronic patients, immunoblotting was performed also in liver tissue.
Low FAH activity may be caused by a "pseudodeficiency" gene (1, 7). Healthy individuals who are homozygotes for the pseudodeficiency gene or compound heterozygous for pseudodeficiency and tyrosinemia have enzyme activity in fibroblasts nearly as low as that in tyrosinemia patients. If one or both parents in a tyrosinemia family have a compound heterozygous genotype, prenatal diagnosis by enzyme assay is not feasible because a low enzyme activity is not conclusive for tyrosinemia (8). If, in such families, the pseudodeficiency gene product gave immunoreactivity but the tyrosinemia gene product did not, immunoblotting could be of help in prenatal diagnosis. To decide this, fibroblast extracts from an individual presumably homozygous for the pseudodeficiency gene and from three tyrosinemia families with complex genotypes were investigated for immunoreactive FAH protein.
Our results show that few tyrosinemia patients, even among those with the chronic type, have immunoreactive FAH protein.
The pseudodeficiency gene product did not give significant immunoreactivity in fibroblast extracts.
MATERIALS AND METHODS
Hereditary tyrosinemia type I (McKusick 27670) is an inborn error of metabolism due to deficiency of FAH (EC 3.7.1.2), the
Patientlperson material. The subjects were 28 patients with last enzyme in the degradation of tyrosine (1). The disorder is hereditary tyrosinemia type I, three parent couples in which one characterized by renal tubular dysfunction with secondary hy-or both parents were compound heterozygous for the tyrosinemia pophosphatemic rickets, and progressive liver damage. Hepato-and pseudodeficiency genes, and one healthy adult individual cellular carcinoma is frequently encountered (2). There is a presumably homozygous for the pseudodeficiency gene (7). In considerable heterogeneity in the clinical picture, and the disor-all 35 individuals, immunoblotting was performed in fibroblast der is referred to as acute or chronic. In the acute form, the extracts. In two tyrosinemia patients, liver tissue was also invespatients become severely ill during the first months of life and tigated. The diagnosis of tyrosinemia was in all patients estabmay die of liver failure in infancy. In the chronic form, symptoms lished by demonstration of elevated excretion of succinylacetone appear later and are usually dominated by rickets until the liver in urine and by deficiency of FAH activity in fibroblasts and in disease becomes life-threatening because of advanced cirrhosis liver tissue when available. When defining the groups for this or development of hepatocellular carcinoma. investigation, we accepted as acute and chronic patients only Recently, immunoblot analyses have shown that patients with those in whom the age of presentation, severity of symptoms, 44 KVITTINGEN ET AL given below. All controls were Caucasians of Norwegian or Dutch origin.
Acute form of tyrosinemia. This group consisted of eight patients of mixed ethnic origin. All patients had severe symptoms of liver disease before the age of 4 mo. Seven died within I y of age, and one had a liver transplant at 12 mo of age.
Chronic ,form of tyrosinemia. This group consisted of seven patients. Five were Norwegian, one was British, and the last was Turkish. The patients had no symptoms in early childhood, and the diagnosis of all patients was established after the age of 4 y. All except one Norwegian patient presented with rickets, and all the patients survived in good clinical condition to at least 8 y of age. Treatment was with a low phenylalanine/tyrosine diet and/ or vitamin D supplementation, except for one patient who received no treatment. The two patients from whom liver tissue was available both presented at the age of 6 y with rickets and had liver transplants after the age of 20 y. Clinical details on three of the Norwegian patients have been reported previously (9-I 1).
"Intermediate" group. This group consisted of 10 patients of Scandinavian or Turkish origin. All presented within 12 mo of age. Generally, symptoms were moderate in infancy, but one patient had rather severe symptoms of liver disease at the age of 7 wk. All survived to at least 2 y of age; one was I8 y old at the time of the investigation. Brief individual case histories are given in Table 1 .
Pseudodeficiency and tyrosinemia. A 41-y-old healthy female presumed to be homozygous for the pseudodeficiency gene (7) and three tyrosinemia families with complex genotypes were investigated for FAH immunoreactivity in fibroblasts. Family 1, in which the father was compound heterozygous for tyrosinemia and pseudodeficiency, has been reported previously (8) . The child with tyrosinemia in this family presented at 12 mo of age with abdominal distension, hepatomegaly, jaundice (slight), abnormal liver tests, and rickets. With dietary treatment from 1 y of age, the rickets healed but the liver dysfunction persisted. The patient died at 4 y of age from hepatocellular carcinoma. In family 2, the father was compound heterozygous for tyrosinemia and pseudodeficiency. The affected daughter had renal tubular defects and prolonged clotting time at the age of 3 mo. At 17 mo of age, when the diagnosis was settled, she had rickets and slightly pathologic liver tests. A liver biopsy showed cirrhosis. The rickets healed on dietary treatment, and at 2.5 y of age she was in good general condition with normal liver tests. In family 3, both parents, who are Pakistani and are double first cousins, had a compound heterozygous genotype for tyrosinemia and pseudodeficiency. Their affected child was diagnosed on the neonatal screen for phenylketonuria when an increase of tyrosine was found. The baby had no clinical symptoms. A low tyrosine/ phenylalanine diet was started at age 7 wk. At age 2.5 y, he was clinically well with slightly abnormal liver tests and hepatomegaly. He also had hyperthrophic obstructive cardiomyopathy (12).
Preparation offibroblast and liver extracts for immunoblotting. Fibroblasts were cultured in minimum essential medium (modified) (Flow Laboratories, Inc., Irvine, Scotland) supplemented with newborn calf serum (17%) (National Institute of Health, Oslo, Norway), glutamine, and antibiotics and harvested with trypsin. The cell suspensions were washed three times in physiologic saline, and the cell pellets were frozen at -70°C. Liver tissue was obtained at liver transplantation, and the tissue was immediately frozen at -70°C. Liver tissue was homogenized in 0.025 mol/L K-phosphate buffer, pH 7.2. Fibroblasts were homogenized in 300 FL of the same buffer. The protein concentration was determined by the Lowry method (13), and aliquots containing 50 pg of protein were treated with trichloroacetic acid, final concentration 10%. After standing on ice, the precipitated protein was centrifuged (10 min at 5000 x g). The supernatant * lmmunoblots of fibroblasts from the patients are shown in Figure 3 . As indicated, patients D, E, and F have cross-reactive material present, whereas the others are negative. 1' CRM, cross-reactive material.
IMMUNOBLOT ANALYSES IN TYROSINEMIA PATIENTS was removed, and the protein was dissolved in sample buffer (4)
and neutralized with 2 M Tris.
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Assay of FAH. Assay of FAH in fibroblasts and liver tissue was performed as reported previously (14). Enzyme activity is expressed in units (U), 1 U being the amount of enzyme hydrolyzing 1 pmol of substrate (fumarylacetoacetate) per minute.
Electrophoresis und immunologic detection of FAH protein. Electrophoresis and immunologic detection of FAH protein were 1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4 1 5 1 6 performed as described previously (4). Proteins were separated by discontinuous PAGE (3% stacking gel, 10% separating gel) and transferred to a nitrocellulose filter. After incubation with polyclonal antibodies to bovine FAH, immune complexes were visualized with a second antibody (antirabbit IgG; Sigma Chemical Co., St. Louis, MO) conjugated with alkaline phosphatase.
RESULTS
The FAH activity in fibroblasts of all the tyrosinemia patients was less than 0.15 U/g protein (reference range 2.3-3.9). The pseudodeficiency homozygous individual had an activity of 0.3 U/g protein, whereas the four individuals presumed to be compound heterozygous for tyrosinemia and pseudodeficiency all had activities of 0.2 U/g protein (mean value of at least four determinations) in fibroblasts. In liver tissue, the two tyrosinemia patients had FAH activities of less than 2 U/g protein (reference range 33-66).
None of the eight patients with acute tyrosinemia had demonstrable immunoreactive FAH protein in fibroblast extracts with 50 pg of protein applied as shown in Figure 1 . In two different controls, bands were visible even with 12.5 pg of protein applied.
Among seven patients with chronic tyrosinemia, only two patients had clearly detectable bands of immunoreactive protein in fibroblasts comparable to that of the control, and two additional patients had trace amounts of immunoreactivity (Fig. 2 ). Fig. 1 . Immunoblots of fibroblast extracts from eight patients (P) with acute tyrosinemia (lunes 4-8 and 10-12). Fifty mg of protein were applied. Lanes I, 2, 3, 9, and 1 3 show controls (C) with 50, 25, 12.5,25, and 25 pg of protein, respectively. Fig. 3 . Immunoblots of FAH protein in fibroblasts from 10 tyrosinemia patients (P) with intermediate clinical symptoms (1une.c 4-13; patients A-J described in Table 1 ). Fifty pg of protein were applied. Lunes 1, 2, 3, 14, IS, and 16 show controls (C) with 50, 25, 12.5, 50, 25. and 12 .5 pg of protein. Fig. 4 . Immunoblots of fibroblast extracts from an individual homozygous for the pseudodeficiency gene (lrine 4) and from three tyrosinemia families in which one or both parents were compound heterozygous for the tyrosinemia and pseudodeficiency genes (lancq 5-13). Families 1, 2, and 3 from left to right (see text for individual description). Fifty pg of protein were applied. Controls (C) are shown in lanes I , 2, 3, and 1 4 with 50, 25, 12.5, and 50 pg of protein, respectively. The numbers above the pedigrees refer to the fibroblast FAH activities (U/g protein). The reference range for FAH in fibroblasts was 2.3-3.9 U/g protein. In Figure 3 , immunoblots of fibroblast extracts from patients in the intermediate group are shown. Three patients, D, E, and F (Table I) , had amounts of cross-reactive material comparable to that of a control, and seven were negative for cross-reactive material. One patient, A, had a trace of immunoreactivity evident on the original blot. Figure 4 shows immunoblots of fibroblasts from the individual presumed to be homozygous for the pseudodeficiency gene and from the three tyrosinemia families with complex genotypes. The pseudodeficiency homozygous individual had only traces of immunoreactive protein. In family I , the father, who is compound heterozygous for tyrosinemia and pseudodeficiency, had a slight amount of cross-reactive material, whereas the affected daughter was negative. In family 2, both the affected child and the compound heterozygous father had some immunoreactive protein, indicating that the tyrosinemia gene product gave some immunoreactivity in this family. None of the members in family 3, in which both parents are compound heterozygotes, had immunoreactive FAH protein. The two ordinary heterozygous mothers in families 1 and 2 had amounts of cross-reactive material comparable to that of the control.
Immunoblots of liver tissue extracts from two chronic patients are given in Figure 5 . One patient had no immunoreactivity in liver tissue, and this patient had only a trace of cross-reactive material in fibroblast extract. The other patient had a clear band in liver tissue, but the amount of cross-reactive material was somewhat reduced compared with that of the control. This patient also had distinct immunoreactivity in fibroblasts. Acute and chronic tyrosinemia refer to clinical findings, and with chronic tyrosinemia (Iunes 4-10). Fifty pg of protein were applied. no clear definition of these terms exists. Environmental factors, Lanes I, 2, 3, 11, 12 , and 1 3 show control (C) samples with 50,25, 12.5, intercurrent infections, and the background genetic makeup of
